Unleashing the Promise of Cell Therapy for Cancer & Autoimmune Diseases
Time: 9:30 am
day: Conference Day One
Details:
- Highlighting how Atara Bio is innovating next-generation CAR-Ts with the only allogeneic T-cell platform with an approved product
- Focusing on how EBV T-cell biology and novel CAR technologies can address the current limitations of autologous and other allogeneic CAR approaches
- Describing ATA3219, Atara Bio’s allogeneic CAR-T targeting CD19, for the potential treatment of SLE and NHL
